Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1876 studies found for:    myeloma
Show Display Options
Rank Status Study
1 Active, not recruiting Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: aMILs;   Biological: Allogeneic Myeloma Vaccine
2 Recruiting Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Condition: Multiple Myeloma
Intervention:
3 Completed
Has Results
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Myeloma Immunoglobulin Idiotype Vaccine;   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine Sulfate;   Drug: Methotrexate;   Biological: GMCSF (granulocyte macrophage colony stimulating factor);   Biological: GCSF (granulocyte colony stimulating factor)
4 Terminated
Has Results
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
5 Recruiting Role of Osteocytes in Myeloma Bone Disease
Condition: Multiple Myeloma
Intervention:
6 Recruiting Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: TH-302;   Drug: TH-302 and bortezomib
7 Completed Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Conditions: Cancer;   Myeloma;   Multiple Myeloma
Intervention: Drug: Bortezomib
8 Recruiting A Phase 1 Study Evaluating CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: CB-5083;   Drug: Dexamethasone
9 Recruiting Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Fludarabine
10 Recruiting Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Condition: Multiple Myeloma
Intervention:
11 Active, not recruiting Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: pomalidomide
12 Completed
Has Results
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Ruxolitinib 25 mg;   Drug: Dexamethasone 40 mg
13 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
14 Completed Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Conditions: Graft vs Host Disease;   Multiple Myeloma
Interventions: Drug: Myeloma Immunoglobulin Idiotype Vaccine-KLH;   Drug: GM-CSF
15 Active, not recruiting Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib + Dexamethasone
16 Recruiting Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Biological: Allogeneic Myeloma Vaccine;   Biological: Prevnar-13
17 Active, not recruiting
Has Results
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Patients With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
Condition: Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: dexamethasone
18 Completed High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: High-Dose Sequential Chemotherapy followed by ASCT
19 Completed Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: CC-5013
20 Active, not recruiting Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: bortezomib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years